Kinfo
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc.

AMLXNASDAQHealthcare·US · USD
$28.35
-1.94 (-6.40%)
Prices as of November 16, 2026 · live

Price

Key statistics

Valuation
Market cap3.89B USD
Enterprise value3.13B USD
Trailing P/E2.54
Forward P/E-26.83
PEG ratio-0.17
Price / sales0.00
Price / book5.17
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-19.11%
Return on equity-30.06%
Income (TTM)
Revenue0.00 USD
Gross profit-92.43M USD
EBITDA-175.45M USD
Net income-163.20M USD
Diluted EPS-$1.43
Rev. growth (YoY)0.00%
Balance sheet
Total cash768.13M USD
Total debt4.94M USD
Debt / equity0.66
Current ratio26.81
Book value / share$5.86
Cash flow (TTM)
Operating cash flow-129.88M USD
Levered free cash flow-80.52M USD
Shares & price
Shares outstanding111.37M
Float112.63M
Held by institutions97.87%
Beta-0.08
50-day MA$29.65
200-day MA$20.80
52-week high$41.14
52-week low$10.83
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-11-05-0.37-0.38−2.70%2026-08-06-0.36-0.39−8.33%2026-05-07-0.34-0.37−8.82%2026-04-080.350.57+62.86%
About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases with significant unmet medical needs. The company’s current pipeline centers on endocrine and neurodegenerative disorders, with avexitide as its lead investigational program. Avexitide is being studied as a first-in-class GLP-1 receptor antagonist for conditions linked to excessive insulin activity, including post-bariatric hypoglycemia and congenital hyperinsulinism. Amylyx also advances additional investigational therapies across other rare and serious diseases, reflecting a research portfolio built around well-defined biological targets and measurable clinical outcomes. Headquartered in Cambridge, Massachusetts, Amylyx Pharmaceuticals plays a role in the biotechnology market as a developer of targeted treatments for patients facing limited therapeutic options.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Joshua B. Cohen
Employees
136
Headquarters
Cambridge, MA, United States
Website
amylyx.com

Frequently asked questions about Amylyx Pharmaceuticals, Inc.